Memantine is a prescription medication used to treat moderate to severe Alzheimer’s disease. It doesn’t cure or reverse Alzheimer’s, but it can slow the worsening of symptoms like memory loss, confusion, and difficulty with everyday tasks. It’s one of only a handful of drugs approved specifically for the later stages of the disease, and it works through a different mechanism than the other major class of Alzheimer’s medications.
How Memantine Works in the Brain
In a healthy brain, a chemical messenger called glutamate plays a key role in learning and memory. But in Alzheimer’s disease, glutamate signaling goes haywire. Too much glutamate overstimulates nerve cells, gradually damaging and killing them in a process called excitotoxicity. Memantine blocks the specific receptors (called NMDA receptors) that glutamate latches onto, dialing down that toxic overstimulation while still allowing normal signaling to occur. Think of it as a filter that blocks the harmful noise without silencing the useful signals.
This mechanism sets memantine apart from cholinesterase inhibitors like donepezil, which work by boosting levels of a different brain chemical involved in memory. Because the two drug classes target different pathways, they’re often used together.
What to Expect From Treatment
Memantine is not a dramatic intervention. It won’t restore lost memories or reverse cognitive decline. What it can do is slow the rate at which symptoms worsen, helping people maintain daily functioning for longer. In clinical studies, small but measurable improvements in daily living activities appeared within the first four weeks of treatment, and two out of three outcome measures showed that benefits persisted through 6 to 12 months of therapy.
The medication is started at a low dose and gradually increased over several weeks. For the extended-release version (originally sold as Namenda XR), the schedule looks like this: 7 mg daily in week one, 14 mg in week two, 21 mg in week three, and the full target dose of 28 mg daily by week four. This slow ramp-up helps minimize side effects. The immediate-release version follows a similar titration but is taken twice daily instead of once.
Combination With Donepezil
For people with moderate to severe Alzheimer’s, combining memantine with donepezil often works better than either drug alone. A network meta-analysis found the combination therapy outperformed monotherapy across four key dimensions: cognition, global assessment, daily activities, and neuropsychiatric symptoms like agitation and aggression. The FDA approved a fixed-dose combination pill (brand name Namzaric) that packages both drugs into a single daily capsule, though the European Medicines Agency declined to approve a similar product, citing insufficient evidence at the time.
The combination may also be more cost-effective in the long run. While the upfront medication cost is higher, the slower rate of clinical progression can reduce the overall burden of care.
Off-Label Uses
Doctors sometimes prescribe memantine for conditions beyond Alzheimer’s, based on varying levels of evidence.
- Obsessive-compulsive disorder (OCD): The strongest off-label evidence. A systematic review and meta-analysis found that people with moderate to severe OCD who added memantine (20 mg daily) to their existing medication were 3.6 times more likely to respond to treatment than those adding a placebo. At least 8 weeks of use appears necessary.
- Vascular dementia: A Cochrane review found a small benefit for cognition and mood, though not for overall clinical ratings or daily functioning.
- ADHD and treatment-resistant schizophrenia: Some clinical evidence supports memantine as an add-on treatment for both conditions, though it’s far less commonly used for these than for OCD.
- Autism spectrum disorder: A 2025 study published in JAMA Network Open found that 56% of youth (ages 8 to 17) taking memantine showed meaningful gains in social functioning, compared with 21% on placebo. The benefits were strongest in participants who had abnormally high brain glutamate levels: 80% of those individuals responded to memantine versus 20% on placebo. However, this was a small trial of 42 participants, and larger studies are needed before memantine could be considered a standard treatment for autism.
Common Side Effects
Most people tolerate memantine well, especially compared to many psychiatric and neurological medications. The most frequently reported side effects in clinical trials were dizziness, headache, confusion, diarrhea, and constipation. These tend to be mild and are less likely to occur when the dose is increased gradually as recommended.
Drug Interactions and Cautions
Because memantine works by blocking NMDA receptors, combining it with other drugs that block the same receptors can amplify side effects. The main ones to watch for are amantadine (used for Parkinson’s and the flu), dextromethorphan (found in many over-the-counter cough medicines), and ketamine. If you’re taking any of these, your prescriber needs to know.
Memantine is cleared through the kidneys, so medications that compete for the same kidney transport system can cause memantine to build up in the bloodstream. Certain antacids and urinary alkalizing agents (like sodium bicarbonate) can also slow memantine’s excretion by changing the pH of urine. For people with severe kidney impairment, the maximum recommended dose is cut in half: no more than 14 mg daily for the extended-release version. Mild or moderate kidney problems don’t require a dose change.